Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases.
Our Phase 3 lead asset, EryDex, is the first product in development that leverages our proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince’s AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response.
EryDex is composed of dexamethasone sodium phosphate (DSP) encapsulated in autologous red blood cells targeted to treat a rare pediatric neurodegenerative disease called Ataxia-Telangiectasia, or A-T. We are currently enrolling the pivotal Phase 3 NEAT study, which is an international, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the neurological effects of EryDex in patients with A-T. The Phase 3 NEAT trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), and we expect to report topline results in the fourth quarter of 2025 with a potential New Drug Application (NDA) submission to the FDA and a Marketing Authorization (MAA) submission to the European Medicines Agency (EMA) in 2026, assuming positive study results. Additionally, Quince was granted Fast Track designation by the FDA for the company’s EryDex System for the treatment of patients with A-T based on the potential for EryDex to address A-T's high unmet need.
Company Details
- Employees
- 28
- Founded
- -
- Address
- 611 Gateway Blvd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.quincetx.com
- HQ
- South San Francisco, California
Quince Therapeutics Questions
Quince Therapeutics's website is http://www.quincetx.com
Quince Therapeutics's LinkedIn profile is https://www.linkedin.com/company/quincetx-inc
Quince Therapeutics has
28 employees.
View email and phone details for 28
employees at Quince Therapeutics.
Quince Therapeutics's industry is
Biotechnology Research
Quince Therapeutics's top competitors are
Eradivir,
Spark Therapeutics, Inc.,
Jasper Therapeutics,
Denali Therapeutics,
Bridgebio,
Lighthouse Pharmaceuticals,
Arsenal Biosciences, Inc.,
Geom Therapeutics,
Rani Therapeutics,
Quince Therapeutics Spa.
Quince Therapeutics's categories are Biotechnology Research
Quince Therapeutics's founding year is 2012
